Early access

Long-acting CAB/RPV in people with suboptimal adherence: IMPALA study results at 48 weeks

Potential for once-monthly oral PrEP using MK-8527

Five doses a week could be a safe option for adults: crisis response to ART stock-outs

5-on 2-off dosing is inferior to continuous ART in BREATHER Plus – but no difference in clinical outcomes

Signal that sliver of PEPFAR might be salvaged

IAS 2025: “We will not be erased” – a community Call to Action

13th IAS Conference on HIV Science (IAS 2025): Introduction and early reports

HIV cure research at IAS 2025

Global Fund plans for lenacapavir PrEP in selected countries

Featured AIDS quilts at the Tate: reflection and also anger

US government has altered more than 100 scientific databases since 20 January